RHEACELL GmbH & Co. KG
- Biotech or pharma, therapeutic R&D
- Rare & Orphan (Epidermolysis Bullosa)
- Asset: EBESANAR: systemic, intra venous treatment
- Drug substance: Allogeneic ABCB5-positive mesenchymal stem cells (off the shelf)
- Status: Late stage; Top line data available by Q1 2026
- Partnering Opportunity: USA and/or ROW (without EU, MENA, Turkey, Israel - please see press release in the shared content)
RHEACELL, a clinical stage biopharmaceutical stem cell company based in Heidelberg, Germany.
RHEACELL is actively seeking worldwide commercial partners for our highly differentiated, systemic therapy, EBESANAR.
This innovative treatment is currently in a pivotal Phase 3 trial in the US and Europe for recessive dystrophic epidermolysis bullosa (RDEB), a rare and devastating orphan disease, with top-line results anticipated in Q1 2026.
NO SERVICE PROVIDERS, THANKS!
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}